Publication: Primary Results of STIMULUS-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Description
Keywords
Citation
WoS Q
Q1
Scopus Q
Q1
Source
Blood
Volume
140
Issue
Start Page
2063
End Page
2065